No Data
No Data
No Data
No Data
No Data
Express News | Novartis Pharms Corp Gets FDA New Drug Application Approval For VIJOICE
BenzingaApr 25 11:09 ET
Novartis Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/24/2024 18.83% BMO Capital $114 → $116 Maintains Market Perform 02/23/2024 16.78% BMO Capital → $114 In
BenzingaApr 24 11:02 ET
Company News for Apr 24, 2024
Yahoo FinanceApr 24 09:36 ET
Express News | Novartis AG : BMO Raises Target Price to $116 From $114
Moomoo 24/7Apr 24 06:51 ET
Express News | Novartis And Medicines For Malaria Venture Announced Data From Phase 2/3 CALINA Study, Demonstrating That Formulated Coartem Developed For Babies Weighing Less Than 5Kg With Malaria Has The Required Pharmacokinetic Profile, Good Efficacy, And Safety
Moomoo 24/7Apr 24 05:37 ET
Novartis Partnership Says New Malaria Drug for Babies Effective, Safe in Phase 2/3 Trial
Novartis (NOVN.SW) and the product development partnership Medicines for Malaria Venture on Wednesday said a new formula of malaria drug Coartem for babies showed "good" efficacy and safety in the pha
MT NewswiresApr 24 01:19 ET
No Data
No Data